[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 33 of about 33
1. Shiga Y, Suzuki K, Tsutsumi M, Ishikawa S: Transitional cell carcinoma of the renal pelvis in a patient with cyclophosphamide therapy for malignant lymphoma: a case report and literature review. Hinyokika Kiyo; 2002 May;48(5):301-5
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transitional cell carcinoma of the renal pelvis in a patient with cyclophosphamide therapy for malignant lymphoma: a case report and literature review.
  • Cyclophosphamide is considered to be a bladder carcinogen and there are many reports of secondary bladder cancer, while only a few cases of upper urothelial cancer have been described.
  • A 59-year-old man, who had received cyclophosphamide therapy for malignant lymphoma, was suffering from gross hematuria and consulted our institute.
  • Computerized tomography (CT), intravenous pyelography (IVP) and retrograde pyelography (RP) revealed a left renal pelvic tumor.
  • Histopathological diagnosis of the left renal pelvic tumor was transitional cell carcinoma, invading the renal parenchyma.
  • To our knowledge, this is the third case of cyclophosphamide-induced upper urothelial carcinoma reported in Japan, and the twelfth reported in the English literature.
  • [MeSH-major] Antineoplastic Agents, Alkylating / adverse effects. Carcinoma, Transitional Cell / chemically induced. Cyclophosphamide / adverse effects. Kidney Neoplasms / chemically induced. Lymphoma / drug therapy. Neoplasms, Second Primary / chemically induced
  • [MeSH-minor] Humans. Kidney Pelvis. Male. Middle Aged


2. Shishido T, Itou T, Ono Y, Arai Y, Miki M: [Adenocarcinoma of the renal pelvis and transitional cell carcinoma of the ureter occurring 11 years after radical cystectomy for bladder cancer: a case report]. Hinyokika Kiyo; 2001 Mar;47(3):187-90
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adenocarcinoma of the renal pelvis and transitional cell carcinoma of the ureter occurring 11 years after radical cystectomy for bladder cancer: a case report].
  • We report a case of upper urinary tract carcinoma which recurred 11 years after total cystectomy.
  • Carcinoma in situ was diagnosed pathologically.
  • The pathological diagnosis was transitional cell carcinoma, grade 3, pTis.
  • The right kidney was not visualized on IVP and computed tomography revealed a right renal irregular mass.
  • On the suspicion of a renal pelvic tumor, right total nephroureterectomy was done.
  • The pathologic diagnosis was renal pelvic adenocarcinoma and ureteral transitional cell carcinoma.
  • The patient was treated postoperatively with 3 cycles of systemic chemotherapy and radiotherapy.
  • [MeSH-major] Adenocarcinoma / etiology. Carcinoma, Transitional Cell / etiology. Cystectomy. Kidney Neoplasms / etiology. Kidney Pelvis. Neoplasms, Second Primary / etiology. Postoperative Complications. Ureteral Neoplasms / etiology. Urinary Bladder Neoplasms / surgery
  • [MeSH-minor] Humans. Male. Middle Aged. Time Factors


3. Hasegawa T, Hasegawa N, Asano K, Ikemoto I, Onodera S, Ohishi Y: [Simultaneously detected double malignancies on a duplicated kidney associated with atrophied counterpart: a case report]. Hinyokika Kiyo; 2001 Nov;47(11):789-92
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Simultaneously detected double malignancies on a duplicated kidney associated with atrophied counterpart: a case report].
  • A case of simultaneous double malignant tumor in the same kidney, associating renal cell carcinoma with renal pelvic transitional cell carcinoma, in a 70 year-old-male was reported.
  • Drip infusion pyelography and multidetector-row computed tomography demonstrated a tumor mass on the upper pole of the left kidney and atrophic right kidney.
  • Systemic chemotherapy with CDDP, MTX and ADR was performed preoperatively.
  • Then, hemi-left nephrectomy underwent with the diagnosis of renal pelvic tumor and renal tumor.
  • The surgical specimen was pathologically diagnosed as transitional cell carcinoma of the renal pelvis and renal cell carcinoma of its upper pole.
  • This is the 32nd case of simultaneous occurrence of renal cell carcinoma and transitional cell carcinoma in the same kidney in the Japanese literature.
  • [MeSH-major] Carcinoma, Renal Cell / pathology. Carcinoma, Transitional Cell / pathology. Kidney / abnormalities. Kidney / pathology. Kidney Neoplasms / pathology. Kidney Pelvis. Neoplasms, Multiple Primary / pathology

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11771172.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 13
  •  go-up   go-down


Advertisement
4. Czito B, Zietman A, Kaufman D, Skowronski U, Shipley W: Adjuvant radiotherapy with and without concurrent chemotherapy for locally advanced transitional cell carcinoma of the renal pelvis and ureter. J Urol; 2004 Oct;172(4 Pt 1):1271-5
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant radiotherapy with and without concurrent chemotherapy for locally advanced transitional cell carcinoma of the renal pelvis and ureter.
  • PURPOSE: Transitional cell carcinoma of the upper urinary tract is a relatively uncommon malignancy.
  • The role of adjuvant radiation therapy and chemotherapy is not well defined.
  • We retrospectively reviewed the records of 31 patients who underwent surgery followed by adjuvant radiotherapy with or without concurrent chemotherapy to determine overall outcome as well as impact of concurrent chemotherapy administration.
  • MATERIALS AND METHODS: Between 1970 and 1997, 31 patients with nonmetastatic transitional cell carcinoma of the upper urinary tract (renal pelvis in 13, ureter in 15, and renal pelvis and ureter in 3) were treated with radiotherapy following attempted curative resection.
  • The median radiation dose was 46.9 Gy.
  • Nine patients received methotrexate, cisplatin and vinblastine chemotherapy for 2 to 4 cycles, followed by concurrent cisplatin with radiation.
  • Seven patients (23%) experienced locoregional failure with distant metastases developing in all except 1 within 8 months of locoregional failure diagnosis.
  • On univariate analysis patients had improved 5-year actuarial overall and disease specific survival with the administration of concurrent chemotherapy (27% vs 67%, p = 0.01 and 41% vs 76%, p = 0.06, respectively).
  • CONCLUSIONS: Our series suggests that the addition of concurrent cisplatin to adjuvant radiotherapy improves the ultimate outcome in patients with resected, locally advanced upper tract urothelial malignancies.
  • This regimen should be considered in patients with T3/4 and/or node positive upper tract transitional cell carcinoma.
  • [MeSH-major] Carcinoma, Transitional Cell / drug therapy. Carcinoma, Transitional Cell / radiotherapy. Kidney Neoplasms / drug therapy. Kidney Neoplasms / radiotherapy. Kidney Pelvis. Ureteral Neoplasms / drug therapy. Ureteral Neoplasms / radiotherapy
  • [MeSH-minor] Actuarial Analysis. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Cisplatin / therapeutic use. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Metastasis / pathology. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Neoplasm, Residual / drug therapy. Neoplasm, Residual / pathology. Neoplasm, Residual / radiotherapy. Neoplasm, Residual / surgery. Outcome and Process Assessment (Health Care). Radiation-Sensitizing Agents / therapeutic use. Radiotherapy, Adjuvant. Survival Rate. Ureter / pathology. Ureter / surgery


5. Grubb RL 3rd, Collyer WC, Kibel AS: Transitional cell carcinoma of the renal pelvis associated with hypercalcemia in a patient with autosomal dominant polycystic kidney disease. Urology; 2004 Apr;63(4):778-80
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transitional cell carcinoma of the renal pelvis associated with hypercalcemia in a patient with autosomal dominant polycystic kidney disease.
  • We present a case of transitional cell carcinoma (TCC) of the renal pelvis in a patient with autosomal dominant polycystic kidney disease (ADPKD) who presented with hypercalcemia.
  • Preoperative magnetic resonance imaging findings suggested a diagnosis of TCC.
  • The patient underwent left nephroureterectomy, which confirmed the diagnosis, and received adjuvant chemotherapy.
  • [MeSH-major] Carcinoma, Transitional Cell / epidemiology. Hypercalcemia / epidemiology. Pelvic Neoplasms / epidemiology. Polycystic Kidney, Autosomal Dominant / epidemiology


6. Li XB, Xing NZ, Wang Y, Hu XP, Yin H, Zhang XD: Transitional cell carcinoma in renal transplant recipients: a single center experience. Int J Urol; 2008 Jan;15(1):53-7
MedlinePlus Health Information. consumer health - Kidney Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transitional cell carcinoma in renal transplant recipients: a single center experience.
  • OBJECTIVE: To present a single center experience in managing transitional cell carcinoma (TCC) in Chinese renal transplant (RTx) recipients.
  • The patients with upper tract carcinoma underwent simultaneous bilateral nephroureterectomy or unilateral nephroureterectomy and bladder cuff resection.
  • Intravesical chemotherapy was started and immunosuppressants were adjusted in all patients immediately after the surgery.
  • In one patient, residual and/or recurrent carcinoma in the contralateral pelvis was detected.
  • CONCLUSIONS: Transitional cell carcinoma is the predominant malignancy in Chinese RTx recipients.
  • Risk-adapted screening, strict follow up, standard surgical intervention and dose reduction of immunosuppressants are very important for early diagnosis and treatment of TCC.
  • [MeSH-major] Carcinoma, Transitional Cell / epidemiology. Kidney Transplantation / statistics & numerical data. Urologic Neoplasms / epidemiology
  • [MeSH-minor] Adolescent. Adult. Aged. Child. China / epidemiology. Cohort Studies. Creatinine / blood. Drugs, Chinese Herbal / therapeutic use. Female. Humans. Immunosuppression / statistics & numerical data. Incidence. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int J Urol. 2008 Oct;15(11):1024; author reply 1024 [19138198.001]
  • (PMID = 18184173.001).
  • [ISSN] 1442-2042
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Drugs, Chinese Herbal; AYI8EX34EU / Creatinine
  •  go-up   go-down


7. Inoue K, Kamada M, Slaton JW, Fukata S, Yoshikawa C, Tamboli P, Dinney CP, Shuin T: The prognostic value of angiogenesis and metastasis-related genes for progression of transitional cell carcinoma of the renal pelvis and ureter. Clin Cancer Res; 2002 Jun;8(6):1863-70
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The prognostic value of angiogenesis and metastasis-related genes for progression of transitional cell carcinoma of the renal pelvis and ureter.
  • PURPOSE: We reported previously that angiogenesis evaluated by intratumor microvessel density (MVD), expression of such angiogenic factors as vascular endothelial cell growth factor (VEGF) and basic fibroblast growth factor (bFGF), and the matrix metalloproteinase-9:E-cadherin ratio (M:E ratio) could identify patients with advanced transitional cell carcinoma (TCC) of the bladder for whom chemotherapy and cystectomy will be unsuccessful.
  • In the present study, we evaluated the significance of the M:E ratio as a predictor for prognosis for patients with TCC in the upper urinary tract (TCC-UUT).
  • EXPERIMENTAL DESIGN: We evaluated MVD by immunohistochemistry and the expression of angiogenic and metastasis-related factors by in situ hybridization in 55 nephroureterectomy specimens from patients who received no neoadjuvant therapy.
  • The expression level of matrix metalloproteinase type 9 (MMP-9) and type 2 (MMP-2) and the M:E ratio correlated with MVD.
  • Multivariate analysis indicated that the M:E ratio and E-cadherin expression were independent prognostic factors for disease progression and intravesical recurrence, respectively.
  • CONCLUSION: We suggest that the M:E ratio and E-cadherin expression may be targets for novel therapeutic strategies.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma, Transitional Cell / blood supply. Kidney Neoplasms / blood supply. Neoplasm Proteins / metabolism. Neovascularization, Pathologic / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cadherins / genetics. Cadherins / metabolism. Disease Progression. Endothelial Growth Factors / genetics. Endothelial Growth Factors / metabolism. Female. Fibroblast Growth Factor 2 / genetics. Fibroblast Growth Factor 2 / metabolism. Humans. Intercellular Signaling Peptides and Proteins / genetics. Intercellular Signaling Peptides and Proteins / metabolism. Interleukin-8 / metabolism. Kidney Pelvis / metabolism. Lymphokines / genetics. Lymphokines / metabolism. Male. Matrix Metalloproteinase 2 / genetics. Matrix Metalloproteinase 2 / metabolism. Matrix Metalloproteinase 9 / genetics. Matrix Metalloproteinase 9 / metabolism. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Prognosis. RNA, Messenger / metabolism. Survival Rate. Ureter / metabolism. Urinary Bladder / metabolism. Vascular Endothelial Growth Factor A. Vascular Endothelial Growth Factors

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12060629.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cadherins; 0 / Endothelial Growth Factors; 0 / Intercellular Signaling Peptides and Proteins; 0 / Interleukin-8; 0 / Lymphokines; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / Vascular Endothelial Growth Factor A; 0 / Vascular Endothelial Growth Factors; 103107-01-3 / Fibroblast Growth Factor 2; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


8. Okada T, Tsukazaki H, Itoh M, Nishio Y, Muro H: [Sarcomatoid carcinoma of the renal pelvis: a case report]. Hinyokika Kiyo; 2002 Feb;48(2):75-9
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Sarcomatoid carcinoma of the renal pelvis: a case report].
  • Unexpectedly, macroscopic examination of the resected kidney revealed multiple yellowish nodules located in the renal pelvis and calyces.
  • Histopathologically the nodules consisted of two pattern of malignancy, transitional cell carcinoma and spindle sarcomatous tumor.
  • Immunohistochemical examination showed that spindle cells were stained positive for cytokeratin, and the final diagnosis was sarcomatoid carcinoma of left renal pelvis.
  • Postoperatively, the patient underwent two courses of adjuvant chemotherapy, but metastases to retroperitoneal lymph nodes were noted two months after operation.
  • [MeSH-major] Carcinosarcoma. Kidney Neoplasms
  • [MeSH-minor] Aged. Humans. Kidney Pelvis / pathology. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11968731.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 16
  •  go-up   go-down


9. Ozsahin M, Ugurluer G, Zouhair A: Management of transitional-cell carcinoma of the renal pelvis and ureter. Swiss Med Wkly; 2009 Jun 27;139(25-26):353-6
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of transitional-cell carcinoma of the renal pelvis and ureter.
  • Transitional-cell carcinoma of the renal pelvis or ureter is a relatively rare disease.
  • The treatment of renal pelvis and ureter tumours is open or laparoscopic surgery varying from conservative to more extensive surgical procedures, i.e. radical nephroureterectomy including removal of the contents of Gerota's fascia with ipsilateral ureter and a cuff of bladder at its distal extent.
  • Most available data are from retrospective studies and surgery is the mainstay of treatment.
  • Chemotherapy and/or radiation therapy are possible adjuvant or primary treatment for selected patients; however, prospective studies are needed to confirm their use.
  • [MeSH-major] Carcinoma, Transitional Cell / surgery. Kidney Neoplasms / surgery. Ureteral Neoplasms / surgery
  • [MeSH-minor] Female. Humans. Kidney Pelvis / pathology. Kidney Pelvis / surgery. Male. Neoplasm Staging. Nephrectomy

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19562529.001).
  • [ISSN] 1424-7860
  • [Journal-full-title] Swiss medical weekly
  • [ISO-abbreviation] Swiss Med Wkly
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 41
  •  go-up   go-down


10. Kolla SB, Hemal AK: An unusual case of transitional cell carcinoma of renal pelvis presenting with brain metastases. Int Urol Nephrol; 2007;39(3):747-50
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An unusual case of transitional cell carcinoma of renal pelvis presenting with brain metastases.
  • During an evaluation for primary, he was found to be having transitional cell carcinoma (TCC) of right renal pelvis, for which palliative radical nephroureterectomy was performed, following which he received four cycles of paclitaxel and carboplatin chemotherapy.
  • [MeSH-major] Brain Neoplasms / secondary. Carcinoma, Transitional Cell / secondary. Kidney Neoplasms / pathology. Kidney Pelvis
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / administration & dosage. Combined Modality Therapy. Humans. Magnetic Resonance Imaging. Male. Paclitaxel / therapeutic use. Ureter / surgery


11. Kirkali Z, Tuzel E: Transitional cell carcinoma of the ureter and renal pelvis. Crit Rev Oncol Hematol; 2003 Aug;47(2):155-69
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transitional cell carcinoma of the ureter and renal pelvis.
  • Transitional cell carcinoma (TCC) of ureter and renal pelvis is relatively uncommon.
  • Approximately 20-50% of patients with upper urinary tract (UUT) TCC have bladder cancer at some point on their course, whereas the incidence of UUT TCC after primary bladder cancer is 0.7-4%.
  • Nephroureterectomy with bladder cuff excision has been the mainstay of treatment.
  • Local resection may be appropriate for distal ureteral lesions especially when the disease is low grade and stage.
  • Adjuvant topical therapies appear to be safe but confirmation of any benefits awaits the results of further large studies.
  • More recently, laparoscopic techniques have become a viable alternative to open surgery, but long term cancer control data are lacking.
  • Adjuvant radiotherapy is ineffective, and systemic chemotherapy results in a low complete response rate for patients with metastases.
  • [MeSH-major] Carcinoma, Transitional Cell. Kidney Neoplasms. Ureteral Neoplasms
  • [MeSH-minor] Combined Modality Therapy. Humans. Kidney Pelvis / pathology. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / etiology. Urinary Bladder Neoplasms / therapy

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12900009.001).
  • [ISSN] 1040-8428
  • [Journal-full-title] Critical reviews in oncology/hematology
  • [ISO-abbreviation] Crit. Rev. Oncol. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Number-of-references] 146
  •  go-up   go-down


12. Raman JD, Scherr DS: Management of patients with upper urinary tract transitional cell carcinoma. Nat Clin Pract Urol; 2007 Aug;4(8):432-43
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of patients with upper urinary tract transitional cell carcinoma.
  • Multiple therapeutic options are available for the management of patients with upper urinary tract transitional cell carcinoma (TCC).
  • Radical nephroureterectomy with an ipsilateral bladder cuff is the gold-standard therapy for upper-tract cancers.
  • However, less invasive alternatives have a role in the treatment of this disease.
  • Endoscopic management of upper-tract TCC is a reasonable strategy for patients with anatomic or functional solitary kidneys, bilateral upper-tract TCC, baseline renal insufficiency, and significant comorbid diseases.
  • Select patients with a normal contralateral kidney who have small, low-grade lesions might also be candidates for endoscopic ablation.
  • Distal ureterectomy is an option for patients with high-grade, invasive, or bulky tumors of the distal ureter not amenable to endoscopic management.
  • In appropriately selected patients, outcomes following distal ureterectomy are similar to that of radical nephroureterectomy.
  • Bladder cancer is a common occurrence following the management of upper-tract TCC.
  • Extrapolating from data on bladder TCC, both regional lymphadenectomy and neoadjuvant chemotherapy regimens are likely to be beneficial for patients with upper-tract TCC, particularly in the setting of bulky disease.
  • [MeSH-major] Carcinoma, Transitional Cell / surgery. Urologic Neoplasms / diagnosis. Urologic Neoplasms / surgery
  • [MeSH-minor] Humans. Kidney Neoplasms / diagnosis. Kidney Neoplasms / drug therapy. Kidney Neoplasms / surgery. Kidney Pelvis / pathology. Kidney Pelvis / surgery. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / drug therapy. Urinary Bladder Neoplasms / surgery

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17673914.001).
  • [ISSN] 1743-4289
  • [Journal-full-title] Nature clinical practice. Urology
  • [ISO-abbreviation] Nat Clin Pract Urol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 107
  •  go-up   go-down


13. Freiha F, Srinivas S: Invasive renal pelvis transitional cell carcinoma. J Clin Oncol; 2004 Jul 15;22(14_suppl):4694

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Invasive renal pelvis transitional cell carcinoma.
  • : 4694 Background: Upper tract tumors of the renal pelvis and ureter represent a small proportion of patients with transitional cell carcinoma.
  • We report our experience with invasive renal pelvis and proximal ureter transitional cell carcinoma.
  • METHODS: All patients seen at our institution between 1995 and 2003 with renal pelvis and proximal ureter who had adequate follow up were selected.
  • Of the 37 patients, 13 were ineligible (6= distal ureters; 3=non invasive cancers; 1=urethral cancer; 1=co existing lung cancer; 2=no follow up).
  • RESULTS: The median age was 72(47-92), 2/3 of the patients were men; renal pelvis was the primary site in 21, upper ureter in 3; 13 (54%) were smokers; ten patients (42%)had bladder tumors either preceding the renal pelvis tumor or after; six (25%) of the patients had distant metastases; ten (42%) had nodal metastases;The median overall survival was 27 months.
  • In those patients without nodal metastases, the T stage determined prognosis.
  • Adjuvant chemotherapy in this small series did not have an impact on survival.
  • The overall survival of patients with distant metastases in bladder cancer varies from 9 months to 33 months depending on the performance status and visceral metastases.
  • CONCLUSIONS: The median survival of patients with metastatic renal pelvis and upper tract tumors is worse than bladder cancer.
  • Early detection and adjuvant chemotherapy may have an impact and should be studied in larger number of patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28015643.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Zhang Y, Gu ZY, Tian Z, Yang C, Cai XY: Oral metastasis from primary transitional cell carcinoma of the renal pelvis: report of a case. Int J Oral Maxillofac Surg; 2010 Jul;39(7):737-9
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oral metastasis from primary transitional cell carcinoma of the renal pelvis: report of a case.
  • Transitional cell carcinoma of the renal pelvis is initially a slow growing tumor arising from the transitional epithelium of the mucous membrane of the renal pelvis.
  • Recurrences occur in two forms: superficial bladder cancer and distant metastases.
  • The authors report an unusual case of transitional cell carcinoma of the renal pelvis metastasized to the oral cavity and lung simultaneously in a 74-year-old man, which occurred 1 year after a left nephroureterectomy.
  • The patient underwent six courses of chemotherapy (gemcitabine, oxaliplatin, fluorouracil and nedaplatin), and received radiotherapy for the oral lesion.
  • [MeSH-major] Carcinoma, Transitional Cell / secondary. Kidney Neoplasms / pathology. Kidney Pelvis / pathology. Mouth Neoplasms / secondary
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Fatal Outcome. Follow-Up Studies. Humans. Lung Neoplasms / secondary. Male. Neoadjuvant Therapy. Neoplasm Recurrence, Local / pathology. Nephrectomy. Radiotherapy, Adjuvant. Ureter / surgery

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 International Association of Oral and Maxillofacial Surgeons. Published by Elsevier Ltd. All rights reserved.
  • (PMID = 20236801.001).
  • [ISSN] 1399-0020
  • [Journal-full-title] International journal of oral and maxillofacial surgery
  • [ISO-abbreviation] Int J Oral Maxillofac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  •  go-up   go-down


15. Hara S, Ito K, Nagata H, Tachibana M, Murai M, Hata J: [Choriocarcinoma of the renal pelvis: a case report]. Hinyokika Kiyo; 2000 Feb;46(2):117-21
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Choriocarcinoma of the renal pelvis: a case report].
  • Intravenous pyelography subsequently demonstrated a left non-visualized kidney, and he was admitted for further evaluation.
  • Cystoscopy revealed a bladder tumor around the left ureteral orifice and retrograde pyelography showed a filling defect in the left renal pelvis.
  • The urinary cytology from the left renal pelvis indicated class IV, and the microscopic findings of a bladder biopsy demonstrated grade 1 transitional cell carcinoma.
  • The pathological diagnosis was high grade transitional cell carcinoma with choriocarcinomatous component.
  • After the operation, the serum human chorionic gonadotropin-beta (hCG-beta) level was slightly elevated, and the combination chemotherapy with methotrexate, vinblastine and cisplatin (MVC) was administered.
  • Although the serum hCG-beta level fell to 0.1 ng/ml, after two courses of MVC chemotherapy, bilateral pulmonary metastases appeared in the chest X-ray with increasing hCG-beta levels.
  • Salvage chemotherapy with cisplatin, etoposide and bleomycin (PEB) was performed.
  • After two courses of PEB chemotherapy, the serum hCG-beta level fell to within the normal range and all pulmonary metastases disappeared.
  • [MeSH-major] Carcinoma, Transitional Cell / therapy. Choriocarcinoma / therapy. Kidney Neoplasms / therapy. Neoplasms, Multiple Primary. Urinary Bladder Neoplasms / therapy
  • [MeSH-minor] Aged. Combined Modality Therapy. Humans. Kidney Pelvis. Lung Neoplasms / secondary. Lung Neoplasms / therapy. Male. Treatment Outcome

  • Genetic Alliance. consumer health - Choriocarcinoma.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10769802.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] JAPAN
  • [Number-of-references] 12
  •  go-up   go-down


16. Chung SD, Wang SM, Lai MK, Huang CY, Liao CH, Huang KH, Pu YS, Chueh SC, Yu HJ: Lymphovascular invasion predicts poor outcome of urothelial carcinoma of renal pelvis after nephroureterectomy. BJU Int; 2009 Apr;103(8):1047-51
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphovascular invasion predicts poor outcome of urothelial carcinoma of renal pelvis after nephroureterectomy.
  • OBJECTIVE: To evaluate the significance of lymphovascular invasion (LVI) to predict cancer-specific survival (CSS) in patients with renal pelvic urothelial carcinoma (UC).
  • PATIENTS AND METHODS: In all, 76 patients with primary renal pelvic UC were treated by nephroureterectomy (NU).
  • Inclusion criteria included nonmetastatic renal pelvic UC with no previous history of bladder cancer, concomitant ureteric lesion, or neoadjuvant chemotherapy.
  • At follow-up, eight cancer-related deaths (10.5%) were censored, and 66 patients (85.9%) were alive and disease-free.
  • CONCLUSIONS: Adrenal metastases from primary renal pelvic UCs were rare.
  • The present results suggest that ipsilateral adrenalectomy is not necessary during radical NU for treating patients with renal pelvic UCs.
  • LVI appears to be a better prognostic factor for predicting poor outcome of renal pelvic UC than pT stage or tumour grade when using the current tumour-nodes-metastases staging system.
  • [MeSH-major] Adrenal Gland Neoplasms / pathology. Kidney Neoplasms / surgery. Nephrectomy / methods

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] BJU Int. 2009 Apr;103(8):1143 [19338572.001]
  • (PMID = 19076143.001).
  • [ISSN] 1464-410X
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


17. Yoshimura N, Kanda H, Suzuki R, Yamakawa K, Hayashi N, Arima K, Yanagawa M, Kawamura J: [Cyclophosphamide-induced renal pelvic tumor--a case report]. Hinyokika Kiyo; 2000 Mar;46(3):177-80
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cyclophosphamide-induced renal pelvic tumor--a case report].
  • We report a case of transitional cell carcinoma in the left renal pelvis, which occurred in a 24-year-old man.
  • Drip infusion pyelography revealed a filling defect in the left renal pelvis.
  • A left renal pelvic tumor was strongly suspected on computerized tomography and magnetic resonance imaging.
  • Histological diagnosis of the left renal pelvic tumor was transitional cell carcinoma, grade 2, pT1N0M0.
  • This case seems to be the second case of cyclophosphamide-induced upper urothelial carcinoma reported in Japan.
  • [MeSH-major] Antineoplastic Agents, Alkylating / adverse effects. Carcinoma, Transitional Cell / chemically induced. Cyclophosphamide / adverse effects. Immunosuppressive Agents / adverse effects. Kidney Neoplasms / chemically induced. Neoplasms, Second Primary / etiology
  • [MeSH-minor] Adult. Humans. Kidney Pelvis. Male. Nephrectomy. Retroperitoneal Neoplasms / drug therapy. Rhabdomyosarcoma / drug therapy. Time Factors. Treatment Outcome. Ureter / surgery

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10806575.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] JAPAN
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Immunosuppressive Agents; 8N3DW7272P / Cyclophosphamide
  • [Number-of-references] 12
  •  go-up   go-down


18. Sawazaki H, Okasyo K, Takahashi T, Taki Y, Takeuchi H: [Gluteal muscular metastasis from renal pelvic tumor]. Hinyokika Kiyo; 2008 May;54(5):361-3
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gluteal muscular metastasis from renal pelvic tumor].
  • We present a case of gluteal muscular metastasis from a renal pelvic tumor.
  • A 57-year-old man had undergone right nephroureterectomy and received 2 courses of adjuvant chemotherapy (MEC: methotrexate, epirubicin, cisplatin) for invasive renal pelvic tumor.
  • Five months after the operation, computed tomography (CT) revealed pulmonary metastasis and right adrenal gland recurrence.
  • He underwent 2 courses of chemotherapy (gemcitabine, paclitaxel).
  • Pathological diagnosis was metastatic urothelial carcinoma.
  • Adjuvant chemotherapy (TIN: paclitaxel, ifosfamide, nedaplatin) 3 courses were performed, but postchemotherapy-CT scan showed a new 2.4 cm mass in the right gluteal muscle.
  • He received radiation therapy (total 30 Gy) for the new gluteal mass.
  • The common metastatic sites of renal pelvic tumor are lungs, liver, bone, and lymph nodes.
  • Gluteal muscle is an uncommon site of metastasis of urothelial carcinoma.
  • This is the 1st case of gluteal muscle metastasis from renal pelvic tumor in the literature.
  • [MeSH-major] Buttocks. Carcinoma, Transitional Cell / pathology. Kidney Neoplasms / pathology. Kidney Pelvis. Muscle Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18546862.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


19. Takase Y, Kohno M, Kobayashi T, Tokunaga S, Imamura Y: [Bellini duct carcinoma: a case report]. Hinyokika Kiyo; 2004 Jun;50(6):425-8
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Bellini duct carcinoma: a case report].
  • A 53-year-old man was admitted to our hospital for the extensive examination and treatment of suspicioun of right renal pelvic tumor.
  • Retrograde pyelography (RP), computed tomography (CT) and magnetic resonance imaging (MRI) showed a space-occupying lesion, about 2 cm in diameter, spread from the renal parenchyma to the renal pelvis.
  • Right nephroureterectomy was performed because transitional cell carcinoma was suspected from the histopothology of the frozen section.
  • The gross examination revealed a white tumor in the upper pole, protruding into the renal pelvis with hemorrhagic necrosis.
  • Histological examination showed Bellini duct carcinoma of the papillary type.
  • He received adjuvant combination chemotherapy with M-VAC (Methotrexate, vinblastine, doxorubicin, cisplatin).
  • [MeSH-major] Carcinoma, Renal Cell / diagnosis. Kidney Neoplasms / diagnosis. Kidney Tubules, Collecting
  • [MeSH-minor] Humans. Magnetic Resonance Imaging. Male. Middle Aged. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15293743.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 8
  •  go-up   go-down


20. Abe T, Konari S, Ogata M, Komatsu S, Satoh T: [A case of CEA-producing renal pelvic and ureteral cancer]. Hinyokika Kiyo; 2003 Feb;49(2):75-9
Genetic Alliance. consumer health - Kidney cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of CEA-producing renal pelvic and ureteral cancer].
  • We report a case of carcinoembryonic antigen (CEA)-producing renal pelvic and ureteral cancer.
  • On ultrasonography and CT scan, right hydronephrosis with the renal pelvis and ureteral tumor were detected, and he was referred to our hospital.
  • CA19-9 was also positive both in the tumor cells and normal epithelium of the renal tubules.
  • Postoperatively, multiple lung metastases developed despite chemotherapy and the patient died 4 months after surgery.
  • CEA had transiently decreased postoperatively, but then increased with lung metastases, apparently related to the state of cancer.
  • [MeSH-major] Biomarkers, Tumor / blood. Carcinoembryonic Antigen / blood. Carcinoma, Transitional Cell / diagnosis. Kidney Pelvis / immunology. Ureteral Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12696186.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-19-9 Antigen; 0 / Carcinoembryonic Antigen
  • [Number-of-references] 17
  •  go-up   go-down


21. Miao M, Kong CZ, Li ZH, Liu XK, Sun ZX: [The clinical study for reducing bladder cancer recurrence after surgical treatment for renal pelvic carcinoma]. Zhonghua Wai Ke Za Zhi; 2009 May 15;47(10):728-30
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The clinical study for reducing bladder cancer recurrence after surgical treatment for renal pelvic carcinoma].
  • OBJECTIVE: To investigate the clinical methods for reducing bladder cancer recurrence after surgical treatment for renal pelvic carcinoma.
  • METHODS: From October 1997 to December 2007, the data of 227 patients undergoing total nephroureterectomy for clinically localized transitional cell carcinoma of the renal pelvis with follow-up results were analyzed retrospectively, including 126 cases of male and 101 cases of female, and the age was 34 to 78 years old.
  • Prophylactic intravesical chemotherapy included 3 method.
  • Method 1 was intraoperative intravesical chemotherapy and then administrated once a week, 10 times in total.
  • Method 2 was intraoperative intravesical chemotherapy and then administrated once a week from the 4(th) week after operation, 10 times in total.
  • Method 3 was intravesical chemotherapy was given once a week from the 4(th) week after operation, 10 times in total.
  • The time of follow-up was 1 to 10 years with regular cystoscopy.
  • Chi-square test and Logistic regression were used to analyzed the recurrence rate of bladder cancer.
  • RESULTS: Recurrence rate of bladder cancer was 27.8% (63/227).
  • The recurrence rates of bladder cancer in patients using technique A and B were 18.0% (7/39) and 12.5% (3/24), respectively (P < 0.05).
  • The postoperative recurrence rates of bladder cancer in patients using 3 kinds of intravesical chemotherapy regimen were 17.9% (11/67), 20.8% (10/48) and 33.3% (17/51), respectively.
  • There was significant difference between the recurrence rates of patients using method 1 and method 3 intravesical chemotherapy (P < 0.05).
  • CONCLUSION: Complete removal of the bladder mucosa circumferentially around the ureteral orifice, administration of the intraoperative intravesical chemotherapy instillation and instillation once a week may be a useful approach to reduce the recurrence of bladder cancer after operation for renal pelvic carcinoma.
  • [MeSH-major] Carcinoma, Renal Cell / surgery. Kidney Neoplasms / surgery. Kidney Pelvis. Urinary Bladder Neoplasms / secondary
  • [MeSH-minor] Adult. Aged. Chemotherapy, Cancer, Regional Perfusion. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / prevention & control. Postoperative Care. Retrospective Studies

  • Genetic Alliance. consumer health - Kidney cancer.
  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19615202.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


22. Oka H, Shiraishi Y, Negoro H, Iwamura H, Moroi S, Soeda A, Takeuchi H, Kawakita M: [Clinical review of conservative management of upper urinary tract transitional cell carcinoma]. Hinyokika Kiyo; 2006 Apr;52(4):249-53
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical review of conservative management of upper urinary tract transitional cell carcinoma].
  • We reviewed 18 patients with transitional cell carcinoma of the renal pelvis and ureter undergoing nephron-sparing surgery between April 1990 and Febrary 2003.
  • The tumor site was the renal pelvis in 2, ureter in 13 and ureteral orfice in 2.
  • Eight patients underwent endourological treatment and 10 patients open surgery including partial ureterectomy performed on 8 patient.
  • In the patients with tumors pT2 or higher and/or grade 3, the prognosis was poor which suggests the need for intensive therapy including lymph node dissection and/or adjuvant chemotherapy.
  • [MeSH-major] Carcinoma, Transitional Cell / surgery. Kidney Neoplasms / surgery. Kidney Pelvis. Nephrectomy / methods. Ureteral Neoplasms / surgery

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16686350.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


23. Maruyama T, Kubo M, Shinchou M, Hashimoto T, Mitsui Y, Ueda Y, Suzuki T, Higuchi Y, Qui J, Kondoh N, Nojima M, Yamamoto S, Shima H, Hirota S: [Case with renal pelvic carcinoma with giant hydronephrosis]. Hinyokika Kiyo; 2008 Nov;54(11):727-31
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Case with renal pelvic carcinoma with giant hydronephrosis].
  • Computed tomography (CT) revealed left giant hydronephrosis containing high-density fluid which was suspected of hemorrhage in the renal pelvis.
  • Systemic examination by CT and magnetic resonance imaging (MRI) showed renal pelvic tumors in the left kidney as well as multiple metastatic lesions in the lung, liver and bone.
  • Pathological examination of the left renal pelvic tumors obtained by biopsy showed high-grade urothelial carcinoma.
  • Although systemic and intra-arterial chemotherapy showed partial response in the metastatic lesions, he died of cancer 1 year and 3 months after the first diagnosis.
  • [MeSH-major] Carcinoma, Transitional Cell / diagnosis. Hydronephrosis / etiology. Kidney Neoplasms / diagnosis. Kidney Pelvis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19068727.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 22
  •  go-up   go-down


24. Munakata S, Tahara H, Kojima K, Kishimoto T: Micropapillary urothelial carcinoma of the renal pelvis: report of a case and review of the literature. Med Sci Monit; 2007 Apr;13(4):CS47-52
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Micropapillary urothelial carcinoma of the renal pelvis: report of a case and review of the literature.
  • BACKGROUND: Micropapillary urothelial carcinoma (MPUC) is a rare variant of urothelial carcinoma (UC), which is often advanced at presentation, and carries poor prognosis.
  • We report a rare case of MPUC of the renal pelvis.
  • She had a mass in the left renal pelvis with massive infiltration in the renal parenchyma.
  • Although she received chemotherapy, she died of disease 14 months after operation.
  • CONCLUSIONS: Here we present a rare case of MPUC arising in the renal pelvis with thorough review of the literature.
  • [MeSH-major] Carcinoma, Papillary / pathology. Kidney Neoplasms / pathology. Ureteral Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17392655.001).
  • [ISSN] 1234-1010
  • [Journal-full-title] Medical science monitor : international medical journal of experimental and clinical research
  • [ISO-abbreviation] Med. Sci. Monit.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Poland
  • [Number-of-references] 30
  •  go-up   go-down


25. Okada T, Tsukazaki H, Itoh M, Nishio Y, Muro H: [Renal pelvic cancer representing G-CSF production and hypercalcemia simultaneously: a case report]. Hinyokika Kiyo; 2002 Mar;48(3):155-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Renal pelvic cancer representing G-CSF production and hypercalcemia simultaneously: a case report].
  • Abdominal ultrasonography and computed tomography revealed a left renal tumor with extracapsular extension.
  • Pathological diagnosis of needle biopsy specimen of the primary tumor was transitional cell carcinoma which was suspected to have originated from renal pelvis.
  • Immunohistochemical examination with anti-granulocyte colony-stimulating factor monoclonal antibody demonstrated granulocyte colony-stimulating factor production in cancer cells.
  • The patient underwent a course of systemic chemotherapy, but died two months after diagnosis.
  • To our knowledge, this is the first report of renal pelvic cancer representing granulocyte colony-stimulating factor production and hypercalcemia simultaneously.
  • [MeSH-major] Carcinoma, Transitional Cell / metabolism. Granulocyte Colony-Stimulating Factor / biosynthesis. Hypercalcemia / complications. Kidney Neoplasms / metabolism. Kidney Pelvis

  • Genetic Alliance. consumer health - Kidney cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11993209.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 143011-72-7 / Granulocyte Colony-Stimulating Factor
  • [Number-of-references] 21
  •  go-up   go-down


26. Kawashima A, Takao T, Takaha N, Nishimura K, Nonomura N, Okuyama A, Tsujimoto Y, Aozasa K: [Renal pelvic cancer with tumor thrombus in the vena cava inferior: a case report]. Hinyokika Kiyo; 2004 Dec;50(12):869-72
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Renal pelvic cancer with tumor thrombus in the vena cava inferior: a case report].
  • We report a case of right renal pelvic cancer with tumor thrombus in the inferior vena cava.
  • Computed tomography showed right renal mass.
  • Magnetic resonance imaging revealed tumor thrombus extending into the renal vein and the inferior vena cava.
  • Preoperative diagnosis was renal cell carcinoma with vena caval thrombus.
  • Pathologic evaluation revealed transitional cell carcinoma with tumor thrombus into the vena cava.
  • One course of M-VAC chemotherapy was added and he has been alive for 56 months without recurrence.
  • A literature review of 15 cases of renal pelvic cancer with tumor thrombus in the vena cava in Japan revealed that 7 cases were diagnosed as renal cell carcinoma preoperatively.
  • [MeSH-major] Kidney Neoplasms / pathology. Neoplastic Cells, Circulating / pathology. Vena Cava, Inferior / pathology
  • [MeSH-minor] Aged. Humans. Kidney Pelvis / pathology. Kidney Pelvis / surgery. Male. Nephrectomy. Thrombectomy

  • Genetic Alliance. consumer health - Kidney cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15682860.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 18
  •  go-up   go-down


27. Yasuda K, Kawa G, Kinoshita H, Matsuda T: [Port-site metastasis of an upper urinary tract urothelial carcinoma after laparoscopic nephroureterectomy: a case report]. Hinyokika Kiyo; 2009 Mar;55(3):141-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Port-site metastasis of an upper urinary tract urothelial carcinoma after laparoscopic nephroureterectomy: a case report].
  • We report here a case of ureteral cancer in which port-site metastasis was suspected after a nephroureterectomy.
  • A tumor was found in his left renal pelvis and ureter by a computed tomographic (CT) scan.
  • The patient was diagnosed with a left upper urinary tract cancer with a clinical stage of T2N0M0.
  • The pathological diagnosis was an urothelial carcinoma, grade 2 > 3, INFbeta, pT3, pV1, pN2.
  • He received two courses of MVAC chemotherapy (methotrexate 50 mg, vinblastine 5 mg, adriamycin 50mg, cisplatin 120 mg) postoperatively.
  • Since retroperitoneal lymph node metastasis was observed three months later on a CT scan, the MVAC chemotherapy was repeated for three courses.
  • Nine months later, a tumor was found in the hypodermic beside the port-site, and a needle biopsy confirmed a metastatic urothelial carcinoma.
  • He received two courses of GP chemotherapy (gemcitabine 4,250 mg, paclitaxel 225 mg).
  • [MeSH-major] Carcinoma, Transitional Cell / pathology. Carcinoma, Transitional Cell / surgery. Laparoscopy. Neoplasm Seeding. Nephrectomy. Ureter / surgery. Ureteral Neoplasms / pathology. Ureteral Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19378825.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 17
  •  go-up   go-down


28. Murakami T, Komiya A, Mikata K, Kaneko S, Ikeda I: Cardiac metastasis of renal pelvic cancer. Int J Urol; 2007 Mar;14(3):240-1
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cardiac metastasis of renal pelvic cancer.
  • Seven months previously he had undergone a laparoscopic left nephroureterectomy for a left renal pelvic tumor and was given two cycles of adjuvant chemotherapy (methotrexate, epirubicin and cisplatin).
  • On computed tomography, multiple lung tumors, as well as the right atrial and ventricular mass, were seen.
  • On autopsy, a right atrial and ventricular metastasis of the initial transitional cell carcinoma was found.
  • The patient's cause of death was acute heart failure as a result of cardiac metastasis of his initial renal pelvic carcinoma.
  • [MeSH-major] Carcinoma, Transitional Cell / secondary. Heart Neoplasms / secondary. Kidney Neoplasms / pathology. Kidney Pelvis
  • [MeSH-minor] Aged. Diagnosis, Differential. Echocardiography. Fatal Outcome. Humans. Laparoscopy. Male. Nephrectomy / methods. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Kidney cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17430263.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


29. Kafé H, Verbavatz JM, Cochand-Priollet B, Castagnet P, Vieillefond A: Collecting duct carcinoma: an entity to be redefined? Virchows Arch; 2004 Dec;445(6):637-40
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Collecting duct carcinoma: an entity to be redefined?
  • Collecting duct carcinomas (CDCs) are highly aggressive tumors with poor survival at 1 year and are often metastatic at the time of diagnosis.
  • It has been shown that patients may have better survival when treated with a chemotherapy regimen used for urothelial carcinoma.
  • Such tumors must therefore be recognized, but their pathological diagnosis remains difficult.
  • The two main differential diagnoses are renal pelvis urothelial carcinoma with infiltration of the kidney and/or high-grade and high-stage papillary renal cell carcinoma.
  • The aim of our study was to compare the immunophenotype of 14 CDCs with 6 renal pelvis urothelial carcinomas (RPUC) infiltrating the medulla.
  • The following markers were evaluated: ulex europeus aglutinin (UEA), peanuts aglutinin, vimentin and aquaporin 3 (AQP-3), a membrane component of normal collecting duct and urothelial cells.
  • We were able to define a reproductive urothelial phenotype AQP-3+, vimentin- and UEA+.
  • It coincided with an urothelial-like trabecular and tubular pattern.
  • (1) the trabecular and tubular variant of CDC with the urothelial AQP-3+, vimentin- phenotype can be included in the spectrum of urothelial diseases;.
  • (3) AQP-3 is a marker of interest for improving the histological classification of CDC and unclassified aggressive renal tumors.
  • [MeSH-major] Kidney Neoplasms / pathology. Kidney Tubules, Collecting

  • Genetic Alliance. consumer health - Collecting Duct Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Physiol Renal Physiol. 2000 Jan;278(1):F13-28 [10644652.001]
  • [Cites] J Pathol. 1997 Oct;183(2):131-3 [9390023.001]
  • [Cites] Science. 1992 Apr 17;256(5055):385-7 [1373524.001]
  • [Cites] Cancer. 2002 Jan 1;94(1):111-6 [11815966.001]
  • [Cites] J Urol. 2003 Oct;170(4 Pt 1):1138-40 [14501710.001]
  • [Cites] J Biol Chem. 1998 Apr 3;273(14):8407-12 [9525951.001]
  • [Cites] Am J Physiol. 1995 Nov;269(5 Pt 2):F663-72 [7503232.001]
  • [Cites] Histopathology. 1985 Oct;9(10):1037-50 [2417930.001]
  • [Cites] Histopathology. 1991 Feb;18(2):115-22 [1707029.001]
  • [Cites] Semin Diagn Pathol. 1998 Feb;15(1):54-67 [9503506.001]
  • [Cites] Hum Pathol. 1990 Apr;21(4):449-56 [2318486.001]
  • (PMID = 15480763.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / AQP3 protein, human; 0 / Aquaporins; 0 / Vimentin; 158801-98-0 / Aquaporin 3
  •  go-up   go-down


30. Oida T, Horii Y, Higashi Y, Uchida J: [Case of carcinoembryogenic antigen-producing renal pelvic cancer]. Hinyokika Kiyo; 2009 Jan;55(1):27-30
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Case of carcinoembryogenic antigen-producing renal pelvic cancer].
  • One year earlier, he had visited another hospital for the evaluation of gross hematuria, and had undergone right nephro-ureterectomy with a diagnosis of right renal pelvic cancer.
  • Thus, we diagnosed this case as CEA-producing renal pelvic cancer.
  • Chemotherapy was ineffective.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoembryonic Antigen / analysis. Carcinoembryonic Antigen / biosynthesis. Carcinoma, Transitional Cell / diagnosis. Carcinoma, Transitional Cell / secondary. Kidney Neoplasms / pathology. Kidney Pelvis. Liver Neoplasms / diagnosis. Liver Neoplasms / secondary. Sternum. Thoracic Neoplasms / diagnosis. Thoracic Neoplasms / secondary
  • [MeSH-minor] Humans. Male. Middle Aged. Suicide. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Kidney cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19227209.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen
  • [Number-of-references] 15
  •  go-up   go-down


31. Muranaka T, Kunishima Y, Shigyo M, Kato R, Masumori N, Ito N, Tsukamoto T, Takagi Y, Seki M, Toida I: [Surgical site infection by bacillus Calmette-Guerin (BCG) after radical cystectomy, occurring after intravesical bcg therapy: a case report]. Hinyokika Kiyo; 2007 Aug;53(8):581-4
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical site infection by bacillus Calmette-Guerin (BCG) after radical cystectomy, occurring after intravesical bcg therapy: a case report].
  • A 51-year-old man received 2 courses of intravesical bacillus Calmette-Guerin (BCG) therapy for carcinoma in situ of the bladder.
  • Two years after the therapy, he underwent left radical nephroureterectomy, cystectomy, urethrectomy and construction of an ileal conduit because of left renal pelvic cancer and severe atrophic bladder.
  • The histopathological diagnosis was carcinoma in situ of the left pelvis and ureter, and epithelioid cell granuloma of left kidney, prostate and bladder.
  • After the operation, he developed extensive surgical site infection (SSI) by BCG, the diagnosis of which was delayed.
  • He recovered from the SSI soon after anti-tuberculosis chemotherapy was begun.
  • We discuss the requirements for more prompt diagnosis of SSI by BCG by analysis of this case.
  • [MeSH-major] BCG Vaccine / adverse effects. Carcinoma, Transitional Cell / drug therapy. Cystectomy. Surgical Wound Infection / etiology. Urinary Bladder Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17874552.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / BCG Vaccine
  •  go-up   go-down


32. Kojima K, Tamaki M, Maeda S, Hori T, Nishino Y, Deguchi T: [A case of renal pelvic tumor due to phenacetin abuse]. Hinyokika Kiyo; 2002 May;48(5):293-6
Hazardous Substances Data Bank. PHENACETIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of renal pelvic tumor due to phenacetin abuse].
  • A solid mass was detected in her left renal pelvis on the abdominal computed tomographic (CT) scan.
  • Under the diagnosis of a left renal pelvic tumor, nephrouretectomy was performed in September, 1999.
  • Histopathological diagnosis was grade 2 transitional cell carcinoma.
  • [MeSH-major] Analgesics, Non-Narcotic / adverse effects. Carcinoma, Transitional Cell / chemically induced. Kidney Neoplasms / chemically induced. Kidney Pelvis. Phenacetin / adverse effects. Substance-Related Disorders / complications
  • [MeSH-minor] Aged. Female. Headache / drug therapy. Humans

  • MedlinePlus Health Information. consumer health - Drug Abuse.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Opioid Abuse and Addiction.
  • MedlinePlus Health Information. consumer health - Pain Relievers.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12094713.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Analgesics, Non-Narcotic; ER0CTH01H9 / Phenacetin
  • [Number-of-references] 12
  •  go-up   go-down


33. Check JH, Dix E, Cohen R, Check D, Wilson C: Efficacy of the progesterone receptor antagonist mifepristone for palliative therapy of patients with a variety of advanced cancer types. Anticancer Res; 2010 Feb;30(2):623-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of the progesterone receptor antagonist mifepristone for palliative therapy of patients with a variety of advanced cancer types.
  • BACKGROUND: Mifepristone has been demonstrated to improve longevity and quality of life in mice with spontaneous murine cancer without progesterone receptors and in human colon cancer.
  • The present study evaluated the palliative effect of mifepristone in a variety of different types of human cancer.
  • PATIENTS AND METHODS: Mifepristone was given at 200 mg daily orally with permission from the Food and Drug Administration to people with widely metastatic human cancer no longer responsive to other chemotherapy regimens.
  • RESULTS: Improvement in pain and energy and/or length of life was found in thymic epithelial cell carcinoma, transitional cell carcinoma of the renal pelvis, leiomyosarcoma, pancreatic carcinoma, malignant fibrous histiocytoma and another case of adenocarcinoma of the colon.
  • CONCLUSION: Our data demonstrate a palliative role for the use of mifepristone in cancer therapy.
  • Progesterone receptor antagonists should be given a therapeutic trial in larger controlled studies of various malignancies in humans.
  • [MeSH-major] Hormone Antagonists / therapeutic use. Mifepristone / therapeutic use. Neoplasms / drug therapy. Palliative Care. Receptors, Progesterone / antagonists & inhibitors
  • [MeSH-minor] Adult. Aged. Carcinoma, Transitional Cell / drug therapy. Carcinoma, Transitional Cell / secondary. Colonic Neoplasms / drug therapy. Colonic Neoplasms / pathology. Female. Histiocytoma, Malignant Fibrous / drug therapy. Histiocytoma, Malignant Fibrous / pathology. Humans. Kidney Neoplasms / drug therapy. Kidney Neoplasms / pathology. Leiomyosarcoma / drug therapy. Leiomyosarcoma / secondary. Male. Middle Aged. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / pathology. Survival Rate. Thymus Neoplasms / drug therapy. Thymus Neoplasms / pathology. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • Hazardous Substances Data Bank. MIFEPRISTONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20332480.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Hormone Antagonists; 0 / Receptors, Progesterone; 320T6RNW1F / Mifepristone
  •  go-up   go-down






Advertisement